Navigation Links
AMDL Reports 2007 Financial Results and 2008 Operating Strategy
Date:4/1/2008

TUSTIN, Calif., April 1, 2008 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), headquartered in Tustin, California, with operations in Shenzhen, Jiangxi, and Jilin, China, is a vertically integrated specialty pharmaceutical company. In combination with its subsidiary Jade Pharmaceutical Inc. (JPI), the Company engages in the research, development, manufacture, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. AMDL today announced:

2007 Net Revenues. The Company generated net revenues of $15.0 million from product sales in Fiscal Year 2007 compared to revenues from product sales of $2.1 million in FY 2006, an increase of $12.9 million or 614 percent. JPI was not acquired until September 28, 2006, therefore full year financials are not comparable. Gross profits were approximately $8.1 million in 2007 compared to gross profits of $933,493 in 2006. The Company had weighted average common shares outstanding as of December 31, 2006 and 2007 of 7,117,893 and 11,718,586, respectively.

2007 Net Loss and Net Loss Per Share. For FY 2007 AMDL's comprehensive net loss was $1.26 million or ($0.20) per share compared to a comprehensive net loss of $5.9 million or ($0.82) per share in FY 2006.

4th Quarter 2007 Results. The Company generated net revenues of approximately $5,363,000 from product sales in the fourth quarter of 2007. This is a 161% increase from the same period in 2006 of approximately $2,049,000. Gross profits increased 156% to approximately $2,646,000 compared to approximately $1,035,000 for the same period in 2006. The Company generated income after foreign currency gain of $498,903 of approximately $1,414,000 for the quarter ended December 31, 2007 compared to a comprehensive loss of approximately $3,322,000 for the same period in 2006.

2006 Assets and Liabilities. At December 31, 2007, the Company had total assets of $32,867,178 compared to total assets of $19,240,613 at December 31, 2006. The primary reason for the increase was the receipt of net proceeds of $9,989,797 from private placements in 2007, offset by the purchase of property and equipment of $2,536,163, and the purchase of product licenses of $2,561,773. Cash and cash equivalents totaled $6,157,493 as of December 31, 2007.

2008 Operating Strategy. "AMDL's near and long-term operating strategies focus on funding the growth of JPI's existing product line, obtaining U.S. Food and Drug Administration and China's State Food and Drug Administration approval for DR-70(R), seeking a large pharmaceutical partner for our CIT technology, and funding the research and development of new products. AMDL continues to strengthen its position in the China pharmaceutical marketplace and is highly pleased with our second straight quarter of profitable operations. We anticipate that 2008 will be a great growth year for the Company," said Gary Dreher, AMDL CEO.

About Jade Pharmaceutical: JPI has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiaries, JPI currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.

About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Contact: AMDL, Inc.

Mr. Paul Knopick

AMDL Investor Relations

Direct Line: 949.707.5365

VoiceMail: 714.505.4460


'/>"/>
SOURCE AMDL, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Natural Nutrition Subsidiary Reports Record Year-End Revenue and EBITDA
2. China Shenghuo Reports Full Year 2007 Financial Results
3. Conseco Reports Fourth Quarter and Year-End Results
4. Benda Pharmaceutical Reports Fourth Quarter and Full Year 2007 Financial Results
5. AdCare Health Systems, Inc. Reports Financial Results for 2007
6. Response Biomedical Corporation Reports 2007 Financial Results
7. Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results
8. Iomai Reports Going Concern Qualification in 10-K
9. Hospital for Special Surgery Reports Scores on HCAHPS Survey
10. PreMD Reports Fiscal 2007 Results
11. Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... ... its innovative EcoQube Frame vertical micro-veggies garden on Kickstarter . Surpassing the ... product – with nearly 2,000 consumers (and counting) already backing the campaign. ...
(Date:3/24/2017)... County, NY (PRWEB) , ... March 24, 2017 , ... ... Somers and White Plains, N.Y., is pleased to announce Westchester resident Lauren C. Enea ... a law clerk for the firm, will concentrate her practice in elder law, Medicaid ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... first Certified Medical Reiki™ Master in Frederick, MD. Judy says, “I am passionate ... during what is often a very difficult and challenging time.” , A Certified ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Communion of ... people of God in congregations across the United States. “The Communion of ... in 1964 who has served congregations in seven states throughout his long career ...
(Date:3/23/2017)... ... March 23, 2017 , ... The physicians of KSF Orthopaedic Center PA ... Area. The new location is located at 2255 E. Mossy Oaks Rd., Suite 440, ... newest location will provide patients living in the north Houston area (The Woodlands, Conroe, ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... , Mar. 24, 2017 Research ... Management in the U.S.: Consumer Strategies" report to their ... ... how adults approach and treat their physical pain, emphasizing consumer ... distinct groups: pain sufferers and adults who have selected illnesses/conditions ...
(Date:3/24/2017)...   The Accreditation Council for Medical Affairs ... the pharmaceutical industry has appointed Dr. Jane ... formed scientific advisory board. Dr. Chin will be ... ever medical affairs think tank within the pharmaceutical ... ACMA, please visit  www.medicalaffairsspecialist.org .  Connect with ...
(Date:3/24/2017)... FinancialBuzz.com News Commentary  ... According to new data published Arcview ... legal cannabis market is projected to continue to grow at ... the current presidential administration. The report created by Arcview,s data ... growth in this industry are the passage and subsequent implementation ...
Breaking Medicine Technology: